Fig. 9: Changes in ADA of volunteers. | Gene Therapy

Fig. 9: Changes in ADA of volunteers.

From: Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials

Fig. 9

Comparison of ADA titers before and after administration of different doses of KJ103. A Changes in ADA titers in Chinese volunteers before and after receiving different doses of KJ103 administration (2 in 0.01 mg/kg group, 6 in other groups each). B Changes in ADA titers in New Zealand volunteers before and after receiving different doses of KJ103 administration (2 in 0.01 mg/kg group, 6 in other groups each).

Back to article page